Moderna (MRNA) valuation

Run six valuation models on Moderna with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

MRNA
MRNA

Moderna

MRNA · Healthcare

Current price

206,01 USD

𝕏 Share on X
You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
83.36 B USD
PE (TTM | NTM | +1y)
— | -49.18 | -46.33
Price / Sales
33.37
EV / EBITDA
-48.32
Price / Book
12.17

Cash flow

FCF yield(-1.44 / 206.01)
-0.7%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
-110.46%
Operating margin
-80.79%
Quarterly earnings (YoY)
—
Quarterly revenue (YoY)
—

Balance

Cash
5.17 B USD
Debt
4.23 B USD
Net position
942.00 M USD

Dividend

Dividend yield
0%
Payout ratio
0%
Next payout
—

Price (5 years)

-21.03%
329.63 USD

What the market paid for its earnings

P/E (TTM)36.0×
2040Its own median 6.9×Its own mean 11.7×20212023

Each week's price divided by the earnings per share already reported by that date — four quarters where a company reports them, its last full year otherwise. Loss-making weeks are not drawn. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What analysts expect

Consensus revenue and earnings per share for the periods not yet reported.

Revenue forecast

ReportedEstimate
0500M1BQ4 25: 676.00 M USDQ4 25Q1 26: 389.00 M USDQ1 26Q2 26: 143.00 M USDQ2 26Q3 26: 1.31 B USDQ3 26Q4 26 · Estimate: 597.68 M USD (280.70 M USD – 1.33 B USD)Q4 26Q1 27 · Estimate: 281.41 M USD (77.00 M USD – 462.00 M USD)Q1 27USD

Consensus of 12 analysts for Q4 26 · -11.85% year on year

EPS forecast

ReportedEstimate
-4-20Q4 25: -2.11 · expected -2.60 (+18.88%)Q4 25Q1 26: -3.40 · expected -3.88 (+12.37%)Q1 26Q2 26: -1.97 · expected -2.06 (+4.33%)Q2 26Q3 26: 0.38 · expected -1.25 (+130.29%)Q3 26Q4 26 · Estimate: -2.13 (-4.29 – -0.03)Q4 26Q1 27 · Estimate: -1.76 (-2.27 – -0.93)Q1 27

Consensus of 14 analysts for Q4 26 · -1.16% year on year · adjusted earnings

Analyst consensus from Yahoo Finance. The dashed bar is the average and the whisker runs from the lowest analyst to the highest. On periods already reported, the green or red line marks what had been expected: below the bar means the company beat it. EPS is measured on an adjusted basis, which is what analysts forecast against and is not the accounting profit in the statements.

Revenue

estimate
01B2BQ3 23: 1.83 B USDQ3 23Q4 23: 2.81 B USDQ1 24: 167.00 M USDQ1 24Q2 24: 241.00 M USDQ3 24: 1.86 B USDQ3 24Q3 25: 1.00 B USDQ4 25: 676.00 M USDQ4 25Q1 26: 389.00 M USDQ2 26: 143.00 M USDQ3 26: 1.31 B USDQ3 26Q4 26 · estimate: 597.68 M USDQ4 26USD

EBITDA

-1B0Q3 23: -1.77 B USDQ3 23Q4 23: 209.00 M USDQ1 24: -1.23 B USDQ1 24Q2 24: -1.32 B USDQ3 24: -19.00 M USDQ3 24Q3 25: -135.00 M USDQ4 25: -724.00 M USDQ4 25Q1 26: -1.26 B USDQ2 26: -687.00 M USDQ3 26: 257.00 M USDQ3 26USD

Net income

-3B-2B-1B0Q3 23: -3.63 B USDQ3 23Q4 23: 217.00 M USDQ1 24: -1.18 B USDQ1 24Q2 24: -1.28 B USDQ3 24: 13.00 M USDQ3 24Q3 25: -200.00 M USDQ4 25: -826.00 M USDQ4 25Q1 26: -1.34 B USDQ2 26: -782.00 M USDQ3 26: 162.00 M USDQ3 26USD

Free cash flow

-1B0Q3 23: -1.74 B USDQ3 23Q4 23: 402.00 M USDQ1 24: -1.19 B USDQ1 24Q2 24: -1.46 B USDQ3 24: -1.72 B USDQ3 24Q3 25: -880.00 M USDQ4 25: 891.00 M USDQ4 25Q1 26: -692.00 M USDQ2 26: -563.00 M USDQ3 26: -1.68 B USDQ3 26USD

EPS

-50Q3 23: -9.53Q3 23Q4 23: 0.63Q1 24: -3.07Q1 24Q2 24: -3.33Q3 24: 0.03Q3 24Q3 25: -0.51Q4 25: -2.11Q4 25Q1 26: -3.40Q2 26: -1.97Q3 26: 0.38Q3 26

Cash & debt

CashDebt
02B4BQ3 23 · Cash: 2.93 B USDQ3 23Q4 23 · Cash: 2.91 B USDQ1 24 · Cash: 2.05 B USDQ1 24Q2 24 · Cash: 2.48 B USDQ3 24 · Cash: 1.64 B USDQ3 24Q3 25 · Cash: 1.13 B USDQ3 25 · Debt: 734.00 M USDQ4 25 · Cash: 2.60 B USDQ4 25 · Debt: 1.31 B USDQ4 25Q1 26 · Cash: 1.91 B USDQ1 26 · Debt: 1.30 B USDQ2 26 · Cash: 1.72 B USDQ2 26 · Debt: 1.29 B USDQ3 26 · Cash: 1.20 B USDQ3 26 · Debt: 4.23 B USDQ3 26USD

Return of capital

DividendsBuybacks
0250K500K750K1MQ3 23 · Buybacks: 1.00 M USDQ3 23Q4 23 · Buybacks: 0.00 USDQ4 23Q1 24 · Buybacks: 0.00 USDQ1 24Q2 24 · Buybacks: 0.00 USDQ2 24Q3 24 · Buybacks: 0.00 USDQ3 24USD

Stock-based compensation

050M100MQ3 23: 77.00 M USDQ3 23Q4 23: 79.00 M USDQ1 24: 101.00 M USDQ1 24Q2 24: 112.00 M USDQ3 24: 112.00 M USDQ3 24Q3 25: 125.00 M USDQ4 25: 113.00 M USDQ4 25Q1 26: 104.00 M USDQ2 26: 120.00 M USDQ3 26: 127.00 M USDQ3 26USD

Operating expenses

R&DSG&A
0500M1B2BQ3 23 · R&D: 1.16 B USDQ3 23 · SG&A: 442.00 M USDQ3 23Q4 23 · R&D: 1.41 B USDQ4 23 · SG&A: 470.00 M USDQ1 24 · R&D: 1.06 B USDQ1 24 · SG&A: 274.00 M USDQ1 24Q2 24 · R&D: 1.22 B USDQ2 24 · SG&A: 268.00 M USDQ3 24 · R&D: 1.14 B USDQ3 24 · SG&A: 281.00 M USDQ3 24Q3 25 · R&D: 801.00 M USDQ3 25 · SG&A: 268.00 M USDQ4 25 · R&D: 775.00 M USDQ4 25 · SG&A: 308.00 M USDQ4 25Q1 26 · R&D: 649.00 M USDQ1 26 · SG&A: 173.00 M USDQ2 26 · R&D: 651.00 M USDQ2 26 · SG&A: 216.00 M USDQ3 26 · R&D: 583.00 M USDQ3 26 · SG&A: 282.00 M USDQ3 26USD

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Popular companies